{"filing":{"accession_number":"0001193125-26-286812","cik":"0001778016","ticker":"NBP","company_name":"NovaBridge Biosciences","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"6-k_-_appointment_of_sri.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1778016/000119312526286812/6-k_-_appointment_of_sri.htm"},"events":[{"id":14442,"run_id":12855,"accession_number":"0001193125-26-286812","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The exhibit announces the appointment of Dr. Srishti Gupta as Chief Executive Officer and Board member of NovaBridge Biosciences, effective July 1, 2026. While the announcement also discloses that Xi-Yong (Sean) Fu is stepping down as CEO, the principal disclosed action is Gupta's appointment to the CEO role. The disclosure emphasizes her extensive leadership experience across biopharmaceuticals and global health, and the Board's confidence in her ability to advance the company's pipeline and create shareholder value—a material change in executive leadership at a clinical-stage biopharmaceutical company.","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":[{"id":11877,"accession_number":"0001193125-26-286812","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the appointment of Dr. Srishti Gupta as Chief Executive Officer and Board member of NovaBridge Biosciences, effective July 1, 2026. While the announcement also discloses that Xi-Yong (Sean) Fu is stepping down as CEO, the principal disclosed action is Gupta's appointment to the CEO role. The disclosure emphasizes her extensive leadership experience across biopharmaceuticals and global health, and the Board's confidence in her ability to advance the company's pipeline and create shareholder value—a material change in executive leadership at a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:01:14.395574+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11877,"accession_number":"0001193125-26-286812","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the appointment of Dr. Srishti Gupta as Chief Executive Officer and Board member of NovaBridge Biosciences, effective July 1, 2026. While the announcement also discloses that Xi-Yong (Sean) Fu is stepping down as CEO, the principal disclosed action is Gupta's appointment to the CEO role. The disclosure emphasizes her extensive leadership experience across biopharmaceuticals and global health, and the Board's confidence in her ability to advance the company's pipeline and create shareholder value—a material change in executive leadership at a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:01:14.395574+00:00","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-06-29"}]}